LEQEMBI Market

“LEQEMBI Market Size, Forecast, and Market Insight − 2032” report provides comprehensive insights about LEQEMBI for Alzheimer’s disease in Japan. A detailed picture of the LEQEMBI for Alzheimer’s disease in Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the LEQEMBI for Alzheimer’s disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LEQEMBI market forecast analysis for Alzheimer’s disease in Japan, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Alzheimer’s disease.

Drug Summary

LEQEMBI, developed by Biogen and Eisai, is a humanized IgG1 mAb directed against aggregated soluble (protofibrils) and insoluble forms of Aβ. It is indicated for treating mild cognitive impairment or mild dementia stage of Alzheimer’s disease. 

The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease. LEQEMBI reduces amyloid beta plaques, as evaluated in various clinical trials.

The recommended dosage of LEQEMBI is 10 mg/kg, diluted and then administered via IV infusion for approximately 1 h, once every 2 weeks, to eligible patients with confirmed presence of Aβ pathology before initiating treatment. Enhanced clinical vigilance for amyloid-related imaging abnormalities (ARIA) is recommended during the first 14 weeks of treatment with LEQEMBI.

Eisai further aims to submit a Biologics License Application (BLA) with the US FDA for LEQEMBI SC formulation, by March 2024 and is conducting trials for the same.

Gain a deeper understanding of the Market with DelveInsight’s detailed report @ Alzheimer’s Disease Treatment Market Size 

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the LEQEMBI description, mechanism of action, dosage and administration, research and development activities in Alzheimer’s disease.
• Elaborated details on LEQEMBI regulatory milestones and other development activities have been provided in this report.
• The report also highlights the LEQEMBI research and development activities in Alzheimer’s disease across Japan.
• The report also covers the patents information with expiry timeline around LEQEMBI.
• The report contains forecasted sales of LEQEMBI for Alzheimer’s disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Alzheimer’s disease.
• The report also features the SWOT analysis with analyst views for LEQEMBI in Alzheimer’s disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Alzheimer’s Disease Prevalence

LEQEMBI Analytical Perspective by DelveInsight

• In-depth LEQEMBI Market Assessment

This report provides a detailed market assessment of LEQEMBI for Alzheimer’s disease in Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• LEQEMBI Clinical Assessment

The report provides the clinical trials information of LEQEMBI for Alzheimer’s disease covering trial interventions, trial conditions, trial status, start and completion dates.

Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ Alzheimer’s Disease Treatment Drugs

Report Highlights  

• In the coming years, the market scenario for Alzheimer’s disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LEQEMBI dominance.
• Other emerging products for Alzheimer’s disease are expected to give tough market competition to LEQEMBI and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LEQEMBI in Alzheimer’s disease.
• Our in-depth analysis of the forecasted sales data of LEQEMBI from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LEQEMBI in Alzheimer’s disease. 

Key Questions

• What is the product type, route of administration and mechanism of action of LEQEMBI?
• What is the clinical trial status of the study related to LEQEMBI in Alzheimer’s disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LEQEMBI development?
• What are the key designations that have been granted to LEQEMBI for Alzheimer’s disease?
• What is the forecasted market scenario of LEQEMBI for Alzheimer’s disease?
• What are the forecasted sales of LEQEMBI in Japan?  
• What are the other emerging products available and how are these giving competition to LEQEMBI for Alzheimer’s disease?
• Which are the late-stage emerging therapies under development for the treatment of Alzheimer’s disease?